Having harvested and germinated seeds from her hand pollinated plants, Minushika scored those seedlings for presence or absence of the red fleck and white V leaf marks and assayed for a specific genetic precursor and enzyme need for the production of hydrogen cyanide.
To be specific, Merck (MRK) will test a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, which the drugmaker notes is the first drug with this type of mechanism to advance to this stage of clinical research.